The committee is being consulted between 14 November – 5 December on the market authorisation for the medicinal product for human use “Saxenda – liraglutide”, granted by Decision C(2015)2133(final) and for “Evenity – romosozumab”, a medicinal product for human use.
Early dialogue and frequent interactions between medicine developers, regulators, health technology assessment bodies (HTAs) and patients can play a key role in delivering robust data needed to enable accelerated access of patients to highly innovative therapies that address unmet medical needs. The chair of EMA’s committee for advanced therapies (CAT), Martina Schussler-Lenz, the chair of EMA’s human medicines committee (CHMP), Harald Enzmann, and the head of EMA’s scientific advice office, Spiros Vamvakas describe these interactions through the example of the recent authorisation of Zynteglo (lentiglobin) in a perspective piece published in Clinical Pharmacology & Therapeutics.
On November 21-22, a couple of month after the first-ever High-Level Meeting on Universal Health Coverage (UHC) is taking place during the UN General Assembly, POLITICO is bringing the Annual Health Care Summit to Amsterdam — a world-renowned life science innovation center and the new home of the European Medicines Agency — for what will be its fourth successful edition. We’ll gather the industry’s top minds together with key policymakers, scientists, business leaders and patient representatives to debate on the policy and cooperative innovations to better public health for the whole of society.
By the European Association of Hospital Pharmacists (EAHP)
The 2019 Medicines Shortages Survey seeks to investigate some of the reasons for medicines shortages in hospitals as well as the impact on patients. In addition, it will identify solutions in place as well as best practices currently applied at local, regional and national level.
The survey targets hospital pharmacists, nurses, physicians, other healthcare professionals working in the hospital environment and patients.
The agenda of the meeting is now available.
On Tuesday, 12 November 2019, as part of the Safer Pharma programme, Health Care Without Harm (HCWH) Europe will host a one-day workshop in Brussels to look at a multi-stakeholder approach to pharmaceuticals in the environment. The event will bring together key participants from EU and international institutions, national governments, industry, civil society and academia.